Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia.
Saved in:
| Transliterated Title: | Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia. |
|---|---|
| Authors: | Marcellusi A; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome 'Tor Vergata', Rome - Italia.; Institute for Leadership and Management in Health - Kingston University London, London - UK., Bini C; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome 'Tor Vergata', Rome - Italia., Rotundo MA; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome 'Tor Vergata', Rome - Italia., Cultrera R; Dipartimento di Morfologia, Chirurgia e Medicina sperimentale, Università degli Studi di Ferrara, Ferrara - Italia., Mennini FS; Faculty of Economics, Economic Evaluation and HTA (EEHTA), CEIS, University of Rome 'Tor Vergata', Rome - Italia.; Institute for Leadership and Management in Health - Kingston University London, London - UK. |
| Source: | Global & regional health technology assessment [Glob Reg Health Technol Assess] 2020 Nov 06; Vol. 7, pp. 92-100. Date of Electronic Publication: 2020 Nov 06 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: AboutScience Country of Publication: Italy NLM ID: 9918417986506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2283-5733 (Electronic) Linking ISSN: 22842403 NLM ISO Abbreviation: Glob Reg Health Technol Assess Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2283-5733 |
|---|---|
| DOI: | 10.33393/grhta.2020.2138 |
